These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18753927)

  • 21. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
    Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
    PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
    Underwood MR; Johns BA; Sato A; Martin JN; Deeks SG; Fujiwara T
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):297-301. PubMed ID: 22878423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.
    Berger DS
    Posit Aware; 2008; 19(5):49-51. PubMed ID: 18831079
    [No Abstract]   [Full Text] [Related]  

  • 29. Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
    Grant P; Zolopa A
    J HIV Ther; 2008 Jun; 13(2):36-9. PubMed ID: 18953272
    [No Abstract]   [Full Text] [Related]  

  • 30. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: design and characterization of the enzymatic properties.
    Shadrina O; Krotova O; Agapkina J; Knyazhanskaya E; Korolev S; Starodubova E; Viklund A; Lukashov V; Magnani M; Medstrand P; Karpov V; Gottikh M; Isaguliants M
    Biochimie; 2014 Jul; 102():92-101. PubMed ID: 24594066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
    Huang W; Frantzell A; Fransen S; Petropoulos CJ
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.
    Garrido C; Villacian J; Zahonero N; Pattery T; Garcia F; Gutierrez F; Caballero E; Van Houtte M; Soriano V; de Mendoza C;
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2873-8. PubMed ID: 22450969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
    Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR
    AIDS; 2011 Mar; 25(5):665-9. PubMed ID: 21326075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.
    White KL; Raffi F; Miller MD
    Viruses; 2014 Jul; 6(7):2858-79. PubMed ID: 25054884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.